AI Assistant
Blog
Pricing
Log In
Sign Up
Ladiratuzumab vedotin for metastatic triple negative cancer: preliminary results, key challenges, and clinical potential
Details
Cite
Export
Add to List
This content is not available in your region!
Continue researching
here.
